ENXTPA:VIRPPharmaceuticals
Assessing Virbac (ENXTPA:VIRP) Valuation After 2026 Guidance And 2025 Revenue Update
Virbac (ENXTPA:VIRP) has put fresh numbers on the table, issuing 2026 revenue growth guidance of 5.5% to 7.5% at constant scope and rates, including the impact of the Thyronorm acquisition.
See our latest analysis for Virbac.
Virbac’s latest guidance and 2025 revenue update have come alongside a 7 day share price return of 4.29% and a 1 year total shareholder return of 15.87%, suggesting momentum has been building rather than fading.
If this kind of news driven move has your attention, it...